Wedbush Reiterates Outperform on Sutro Biopharma, Maintains $60 Price Target

Benzinga · 2d ago
Wedbush analyst David Nierengarten reiterates Sutro Biopharma (NASDAQ:STRO) with a Outperform and maintains $60 price target.